๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

โœ Scribed by Mittmann, N.; Au, H.-J.; Tu, D.; O'Callaghan, C. J.; Isogai, P. K.; Karapetis, C. S.; Zalcberg, J. R.; Evans, W. K.; Moore, M. J.; Siddiqui, J.

Book ID
111687043
Publisher
Oxford University Press
Year
2009
Tongue
English
Weight
486 KB
Volume
101
Category
Article
ISSN
0027-8874

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Venous thromboembolism and nonsmall cell
Venous thromboembolism and nonsmall cell lung cancer : A pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials
โœ Lisa K. Hicks; Matthew C. Cheung; Keyue Ding; Baktiar Hasan; Lesley Seymour; Aur ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 174 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND: Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored. ## METHODS: I

Phase II study of flutamide in patients
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study
โœ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

Phase II study of trimetrexate in malign
Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study
โœ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic